semaglutide and tamoxifen The Impact Safety of GLP‐1 Agents and Breast Cancer Your Alternative to Tamoxifen: HR+

Bone Loss

Choline maintains cell membrane integrity and bile production for fat digestion

Study Methodology Inclusion criteria included: BMI over 25 Age between 45 to 70 years No supplement consumption in the past three months No weight loss diet in the past three months No participation in other intervention programs Willingness to lose weight No history of heart, liver, kidney disease, diabetes, hypothyroidism, rheumatoid arthritis, or surgery After signing the informed consent form, participants were randomly assigned to an intervention group (21 individuals) and a control group (22 individuals)

An overview of ongoing clinical trials with GLP-1R agonist and incretin combination therapy is provided in Table 2